Biological response modifiers

APLAR Journal of Rheumatology

Volumn 7, Issue 2, 2004, Pages 179-183

  Rao, U R K ^a   Fatima, Firdaus ^a  

^a Sri Deepti Rheumatology Centre   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; BETA INTERFERON; BIOLOGICAL RESPONSE MODIFIER; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6 ANTIBODY; LIP 394; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 8; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ARTHRITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BEHCET DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DEMYELINATING DISEASE; DRUG EFFICACY; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INFLAMMATORY DISEASE; INHIBITION KINETICS; JUVENILE RHEUMATOID ARTHRITIS; LUPUS ERYTHEMATOSUS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN FAMILY; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT INDICATION; VASCULITIS;

EID: 23444442086     PISSN: 02190494     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2004.00084.x     Document Type: Conference Paper

References (20)

1. Shen WC, Louie SG (1998) Immunology for pharmacy students. Harwood Academic, Amsterdam.
2. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. (1999) Ann Intern Med 130, 478-86.
3. Weinblatt ME, Kremer JM, Bankhurst AD, et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fcfusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340, 253-9.
4. Lipsky PE, van der Heijde DM, St Clair EW, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343, 1954-602.
5. Maini RN, Breedveld FC, Kalden JR, et al. (1998) therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41, 1552-63.
6. Hanauer SB (1999) Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 13, 16-22.
7. Rau R (2002) Adalimumab (a fully human anti-tumor necrosis factor [alpha] monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 61(Suppl. II), 70-73.
8. Campion GV, Lebsack ME, Lookabaugh J, et al. (1996) Dose-range and dose frequency study of recombinant human interleukin-1 receptor antagonist in-patients with rheumatoid arthritis. Arthritis Rheum 39, 1092-101.
9. Cohen S, Hurd E, Gush J, et al. (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46, 614-24.
10. Bresnihan B, Alavro-Gracia JM, Cobby M, et al. (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41, 2196-204.
11. Van Holten J, Plater-Zyberk C, Tak PP (2002) Interferon for treatment of rheumatoid arthritis? Arthritis Res 4, 346-52.
12. Zouboulis CC, Orfanos CE (1998) Treatment of Adamantiades-Behcet disease with systemic interferon alpha. Arch Dermatol 134, 1010-6.
13. Taga T, Kishimoto T (1997) Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15, 797-819.
14. Lee JC, Kumar S, Griswold DE, et al. (2000) Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47, 185-201.
15. Rottapel R (2001) Putting the brakes on arthritis: can suppressors of cytokine signaling (SOCS) suppress rheumatoid arthritis? [Letter]. J Clin Invest 108, 1745-7.
16. Haringman JJ, Kraan MC, Smeets TJM, et al. (2002) Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 46, s136.
17. Papp K, Bissonnette R, Krueger JG, et al. (2001) The treatment of moderate to severe psoriasis with a new anti-CD11 a monoclonal antibody. J Am Acad Dermatol 45, 665-74.
18. Edwards JCW, Szczepanski L, Szechinski J, et al. (2002) Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo-controlled trial in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 46, s197.
19. Cheema GS, Roschke V, Hilbert DM, et al. (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44, 1313-9.
20. McNeeley PA, Iverson GM, Furie RA et al. (2001) Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients. Lupus 10, 526-32.